Log In or Register to Join The Conversation!

This topic has 0 replies, 1 voice, and was last updated 1 year, 10 months ago by Kevin Schaefer.

  • Author
    Posts
    • #18607
      Kevin Schaefer
      Keymaster

      Happy Tuesday everyone!

      As many of you know, Zolgensma (previously known as AVXS-101) is the proprietary gene therapy candidate from AveXis designed to treat spinal muscular atrophy (SMA). We’ve been covering news regarding this drug on our main website and in our podcasts and flash briefings for the past few months. It’s very likely that the drug will be FDA-approved soon.

      As such, we wanted to create a separate sub-forum devoted to Zolgensma. We will be using this forum to post news and updates regarding the treatment, and to talk about what it means for the SMA community as a whole. Though this treatment will only be available to infants with Type I SMA initially, there’s no telling what the future will hold. It’s very possible that it will be made available to adults eventually.

      For now, we will be tracking the information and news here. Thanks for joining us, and please feel free to share your thoughts and perspectives regarding Zolgensma.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Copyright © 2017-2021 All rights reserved.